Chronic low‐dose levodopa therapy in Parkinson's disease

No abstract is available for this paper.

• Publication year

  1984

• Venue

  Neurology

• Publication date

  1984-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/WNL.34.8.991PMID 6540397
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of Parkinson's disease: Problems with a progressing disease

  2005cited by this paper
• Epidemiological survey of dementia in parkinsonism and control population.

  1984cited by this paper
• Current Views on Parkinson’s Disease

  1983cited by this paper
• Alternate day levodopa therapy in parkinsonism

  1982cited by this paper
• Levodopa: long-term impact on Parkinson's disease.

  1981cited by this paper
• Sinemet and the treatment of Parkinsonism.

  1981cited by this paper
• Evidence to support early levodopa therapy in Parkinson disease

  1981cited by this paper
• Drug holiday and management of Parkinson disease

  1980cited by this paper
• Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapy

  1979cited by this paper
• Dementia in Parkinson disease

  1979cited by this paper
• The L‐dopa on‐off effect in parkinson disease: Treatment by transient drug withdrawal and dopamine receptor resensitization

  1978cited by this paper
• Receptor basis for dopaminergic supersensitivity in Parkinson's disease

  1978cited by this paper
• Considerations in the management of parkinsonism

  1978cited by this paper
• Probability and Statistics for Engineers and Scientists.

  1978cited by this paper
• Six years of high-level levodopa therapy in severely akinetic parkinsonian patients.

  1976cited by this paper
• Levodopa and psychometric test performance in parkinsonism–5 years later

  1976cited by this paper
• Mental symptoms in Parkinson's disease during chronic treatment with levodopa

  1976cited by this paper
• "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy.

  1976cited by this paper
• Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients.

  1975cited by this paper
• Parkinson's disease and levodopa. A five-year follow-up and review.

  1974cited by this paper
• Levodopa treatment of Parkinson's syndrome. Improved intellectual functioning.

  1972cited by this paper
• Critical analysis of the disability in Parkinson's disease.

  1968cited by this paper
• Aromatic amino acids and modification of parkinsonism.

  1967cited by this paper
• Parkinsonism

  1967cited by this paper
• Handbook of Statistical Tables

  1964cited by this paper
• Non-parametric Statistical Inference

  1949cited by this paper

• Increased Survival in Contemporary Parkinson’s Disease: A 47-Year Autopsy Study

  2024cites this paper
• Effect of Levodopa on Heat Hypersensitivity and Complex Motor Parkinsonism

  2023cites this paper
• Aging and the Science

  2021cites this paper
• Attempted Suicide in a Parkinsonian Patient Treated with DBS of the VIM and High Dose Carbidopa-Levodopa

  2019cites this paper
• The Locus coeruleus in Parkinson’s disease - from basic research to new translational perspectives -

  2019cites this paper
• Mesencephalic and extramesencephalic dopaminergic systems in Parkinson’s disease

  2019cites this paper
• Medical Treatment of Parkinson’s Disease

  2017cites this paper
• Normal substantia nigra patients treated with levodopa - Clinical, therapeutic and pathological observations.

  2015cites this paper
• Early-onset vs. Late-onset Parkinson’s disease: A Clinical-pathological Study

  2015cites this paper
• Saskatchewan Movement Disorders Program

  2015cites this paper
• Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.

  2015cites this paper
• Initial management of Parkinson’s disease

  2014cites this paper
• Factors Predictive of the Development of Levodopa-Induced Dyskinesia and Wearing-Off in Parkinson's Disease

  2013cites this paper
• Daily motor performance after switching levodopa to melevodopa: an open-label on advanced Parkinson's disease with "delayed-on" and/or"wearing-off".

  2011cites this paper
• Pharmacotherapeutic Approaches of Parkinson’s Disease

  2010cites this paper
• Treatment of Parkinson's disease.

  2009cites this paper
• [Advances in the medical treatment of Parkinson's disease].

  2009cites this paper
• Course in Parkinson disease subtypes

  2009cites this paper
• Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease (Review)

  2009cites this paper
• Effects of Nebicapone on Levodopa Pharmacokinetics, Catechol-O-methyltransferase Activity, and Motor Fluctuations in Patients with Parkinson Disease

  2008cites this paper
• Pharmacokinetic-Pharmacodynamic Interaction between Nebicapone, a Novel Catechol-O-Methyltransferase Inhibitor, and Controlled-Release Levodopa/Carbidopa 200 mg/50 mg

  2008cites this paper
• Neuropathy as a potential complication of levodopa use in Parkinson's disease

  2008cites this paper
• [Early-onset Parkinsonism. A report on a Spanish series].

  2007cites this paper
• Old age and Parkinson's disease.

  2007cites this paper
• Parkinson's Disease Treatment Guidelines 2002 issued by Societas Neurologica Japonica

  2007cites this paper
• Efficacy and safety of herbal medicines for idiopathic Parkinson's disease: A systematic review

  2006influential citation
• Parkinson’s disease management strategies

  2006cites this paper
• Persistent vegetative state in Head injury

  2005cites this paper
• Progress in Clinical Neurosciences: A Forum on the Early Management of Parkinson's Disease

  2005cites this paper
• Deep Brain Stimulation for the Treatment of Parkinson’s Disease

  2004cites this paper
• Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.

  2004cites this paper
• Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease.

  2004cites this paper
• Options in the treatment of motor fluctuations and dyskinesias in Parkinson's disease: a brief review.

  2004cites this paper
• Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off.

  2004cites this paper
• Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.

  2004cites this paper
• Amantadine for dyskinesia in Parkinson's disease.

  2003cites this paper
• Amantadine in Parkinson's disease.

  2003cites this paper
• Chapter 74 – Parkinsonism

  2003cites this paper
• Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa‐induced motor complications

  2003cites this paper
• Epidemiology of Parkinsonism

  2003cites this paper
• Treatment of Parkinson's disease

  2003cites this paper
• L-DOPA THERAPY IN PARKINSON'S DISEASE: AN UPDATE AFTER 30 YEARS OF CLINICAL USE

  2002cites this paper
• Increase of Preproenkephalin mRNA Levels in the Putamen of Parkinson Disease Patients with Levodopa‐Induced Dyskinesias

  2002cites this paper
• Treatment of early Parkinson’s disease

  2002cites this paper
• The effect of stage of Parkinson’s disease at the onset of levodopa therapy on development of motor complications

  2002influential citation
• Progressive supranuclear palsy diagnosis and confounding features: Report on 16 autopsied cases

  2002cites this paper
• Uncertainties in the Pharmacotherapy of Parkinson’s Disease and How to Solve Them

  2002cites this paper
• [Dyskinesia caused by L-DOPA].

  2002cites this paper
• Clinical–Pathological study of levodopa complications

  2002cites this paper
• Elevated levels of ΔFosB and RGS9 in striatum in Parkinson’s disease

  2001cites this paper
• Levodopa prolongs life expectancy and is non-toxic to substantia nigra.

  2001cites this paper
• Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature

  2001cites this paper
• Parkinson's disease: medical and surgical treatment.

  2001cites this paper
• Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson's disease.

  2001cites this paper
• Parkinson’s Disease: Experience with Large Multicentre Trials

  2001cites this paper
• Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease.

  2001cites this paper
• The protective role of levodopa in the human substantia nigra.

  2001cites this paper
• Ropinirole for levodopa-induced complications in Parkinson's disease.

  2001cites this paper
• An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines.

  2001cites this paper
• Cabergoline for levodopa-induced complications in Parkinson's disease.

  2001cites this paper
• Parkinson’s disease: Initial treatment with levodopa or dopamine agonists

  2001cites this paper
• Pramipexole versus bromocriptine for levodopa‐induced complications in Parkinson's disease

  2000cites this paper
• Pramipexole for levodopa-induced complications in Parkinson's disease.

  2000cites this paper
• Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.

  2000cites this paper
• Pergolide for levodopa-induced complications in Parkinson's disease.

  2000cites this paper
• Pramipexole for levodopa-induced complications in Parkinson's disease.

  2000cites this paper
• Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease.

  2000cites this paper
• Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease.

  2000cites this paper
• Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease.

  2000cites this paper
• [Motor complications of treatment with levodopa in Parkinson's disease].

  1999cites this paper
• Pergolide for levodopa-induced complications in Parkinson's disease

  1999cites this paper
• From experimentation to the surgical treatment of Parkinson's disease: prelude or suite in basal ganglia research?

  1999cites this paper
• [Motor and mental complications in the long-term treatment of complicated Parkinson's disease with levodopa].

  1999cites this paper
• Wirkverlust und „Therapieresistenz“

  1999cites this paper
• Therapieempfehlungen der Früh- und Spätphase der Parkinson-Krankheit

  1999cites this paper
• L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach.

  1999cites this paper
• Risk factors for levodopa-induced dyskinesias in Parkinson’s disease

  1999cites this paper
• Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.

  1999cites this paper
• Lisuride for levodopa-induced complications in Parkinson's disease.

  1999cites this paper
• The initial treatment of Parkinson's disease should begin with levodopa

  1999cites this paper
• Rationale for Use of Dopamine Agonists in Parkinson's Disease: Review of Ergot Derivatives

  1999cites this paper
• Motor fluctuations in Parkinson's disease.

  1999cites this paper
• Immediate-release and controlled-release carbidopa/levodopa in PD

  1999cites this paper
• Levodopa in Parkinson’s Disease

  1999cites this paper
• Parkinson's disease and neuropsychological assessment.

  1999cites this paper
• Catechol-O-Methyltransferase Inhibitors in Parkinson’s Disease

  1998cites this paper
• Experimental Models of Parkinson's Disease: From the Static to the Dynamic

  1998cites this paper
• L-DOPA exacerbates amphetamine-induced dopamine depletion.

  1998cites this paper
• Levodopa Toxicity and Apoptosis

  1998cites this paper
• Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions

  1998cites this paper
• Early introduction of dopamine agonists in the long-term treatment of Parkinson's disease

  1998cites this paper
• Burning mouth in Parkinson's disease sufferers.

  1998cites this paper
• Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach.

  1998cites this paper
• A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease

  1998cites this paper
• An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. American Academy of Neurology.

  1998cites this paper
• An algorithm (decision tree) for the management of Parkinson’s disease (2001):

  1998cites this paper
• Advances in the treatment of Parkinson's disease.

  1998cites this paper
• Does timing and dosage of levodopa modify drug-induced dyskinesias and motor fluctuations? A retrospective analysis.

  1998cites this paper
• Does combined levodopa and bromocriptine therapy in Parkinson's disease prevent late motor complications?

  1998cites this paper
• New use for an old drug: amantadine benefits levodopa-induced dyskinesia.

  1998cites this paper